Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiunn H Lin

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry Letters|July 11, 2003
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituentJoseph L Duffy, Thomas A Rano, Nancy J Kevin, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2003
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituentJoseph L Duffy, Brian A Kirk, Nancy J Kevin, et al.
Journal of Medicinal Chemistry|October 4, 2002
Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicityStephen F Brady, Joseph M Pawluczyk, Patricia K Lumma, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strainsJoseph L Duffy, Nancy J Kevin, Brian A Kirk, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavirNancy J Kevin, Joseph L Duffy, Brian A Kirk, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2003
Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoproteinSanjeev Kumar, Gloria Y Kwei, Grace K Poon, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2003
Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virusZhijian Lu, Subharekha Raghavan, Joann Bohn, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
A combinatorial library of indinavir analogues and its in vitro and in vivo studiesYuan Cheng, Thomas A Rano, Tracy T Huening, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2017
Pharmacological and Toxicological Properties of the Potent Oral <i>γ</i>-Secretase Modulator BPN-15606Steven L Wagner, Kevin D Rynearson, Steven K Duddy, et al.
Molecular Cancer Therapeutics|December 14, 2002
A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivoDeborah DeFeo-Jones, Stephen F Brady, Dong-Mei Feng, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|July 11, 2003
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituentJoseph L Duffy, Thomas A Rano, Nancy J Kevin, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2003
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituentJoseph L Duffy, Brian A Kirk, Nancy J Kevin, et al.
Journal of Medicinal Chemistry|October 4, 2002
Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicityStephen F Brady, Joseph M Pawluczyk, Patricia K Lumma, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strainsJoseph L Duffy, Nancy J Kevin, Brian A Kirk, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavirNancy J Kevin, Joseph L Duffy, Brian A Kirk, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2003
Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoproteinSanjeev Kumar, Gloria Y Kwei, Grace K Poon, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2003
Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virusZhijian Lu, Subharekha Raghavan, Joann Bohn, et al.
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
A combinatorial library of indinavir analogues and its in vitro and in vivo studiesYuan Cheng, Thomas A Rano, Tracy T Huening, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2017
Pharmacological and Toxicological Properties of the Potent Oral <i>γ</i>-Secretase Modulator BPN-15606Steven L Wagner, Kevin D Rynearson, Steven K Duddy, et al.
Molecular Cancer Therapeutics|December 14, 2002
A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivoDeborah DeFeo-Jones, Stephen F Brady, Dong-Mei Feng, et al.
Pageof 5